Publication: 4546

Publication: 4546

Efficacy and Safety of Cabozantinib for Advanced Grade 3 Neuroendocrine Tumors After Progression on Prior Therapy: Subgroup Analysis of the Phase 3 CABINET Trial (Alliance A021602)

DOI

Google Scholar

Citation:

Meeting Instance:: ENETS 2025
Year:: 2025
Type:: Abstract
Sub type:: Poster General
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 4745

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:: Exelixis;
Grants:: U10CA180821, U10CA180882; U10CA180820 (ECOG-ACRIN), U10CA180868 (NRG Oncology), U10CA180888 (SWOG)

Corr. Author:
Authors:: Jonathan R. Strosberg Tyler Zemla Susan Geyer Sydney Pulsipher Spencer Behr Nitya Raj Namrata Vijayvergia Arvind Dasari Jeffrey A. Meyerhardt Edward M. Wolin Thorvardur R. Halfdanarson Jennifer A. Chan

Networks:: CA824, FL065, LAPS-MA036, LAPS-MN026, LAPS-NY016, NY021

Study: Alliance-A021602
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: cabozantinib, grade 3 neuroendocrine tumor, pancreatic neuroendocrine tumor, extra-pancreatic neuroendocrine tumor